Please use this identifier to cite or link to this item:
Title: Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer.
Authors: Pérez-Ramírez, Cristina
Cañadas-Garre, Marisa
Alnatsha, Ahmed
Molina, Miguel Ángel
Robles, Ana I
Villar, Eduardo
Delgado, Juan Ramón
Faus-Dáder, María José
Calleja-Hernández, Miguel Ángel
Keywords: Interleukins;Non-small cell lung cancer;Platinum based chemotherapy;Polymorphisms;Survival
metadata.dc.subject.mesh: Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
Disease Progression
Early Detection of Cancer
Genetic Markers
Interleukin-12 Subunit p35
Kaplan-Meier Estimate
Lung Neoplasms
Middle Aged
Polymorphism, Genetic
Prospective Studies
Issue Date: 22-May-2017
Abstract: Surgery is the standard treatment for early-stage NSCLC, and platinum-based chemotherapy remains as the treatment of choice for advanced-stage NSCLC patients with naïve EGFR status. However, overall 5-years relative survival rates are low. Interleukins (ILs) are crucial for processes associated with tumor development. In NSCLC, IL1B, IL6, IL12A, IL13 and IL16 gene polymorphisms may contribute to individual variation in terms of patient survival. The purpose of this study was to evaluate the association between IL gene polymorphisms and survival in NSCLC patients. A prospective cohorts study was performed, including 170 NSCLC patients (114 Stage IIIB-IV, 56 Stage I-IIIA). IL1B (C > T; rs1143634), IL1B (C > T; rs12621220), IL1B (C > G; rs1143623), IL1B (A > G; rs16944), IL1B (C > T; rs1143627), IL6 (C > G; rs1800795), IL12A (C > T; rs662959), IL13 (A > C; rs1881457) and IL16 (G > T; rs7170924) gene polymorphisms were analyzed by PCR Real-Time. Patients with IL16 rs7170924-GG genotype were in higher risk of death (p = 0.0139; HR = 1.82; CI95% = 1.13-2.94) Furthermore, carriers of the TT genotype for IL12A rs662959 presented higher risk of progression in the non-resected NSCLC patient subgroup (p = 0.0412; HR = 4.49; CI95% = 1.06-18.99). The rest of polymorphisms showed no effect of on outcomes. Our results suggest that IL16 rs7170924-GG and IL12A rs662959-TT genotypes predict higher risk of death and progression, respectively, in NSCLC patients. No influence of IL1B rs12621220, IL1B rs1143623, IL1B rs16944, IL1B rs1143627, IL6 rs1800795, IL13 rs1881457 on NSCLC clinical outcomes was found in our patients.
metadata.dc.identifier.doi: 10.1016/j.suronc.2017.05.004
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons